Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Emergent BioSolutions Inc...

    NYSE: EBS · Real-Time Price · USD
    6.26
    -0.34 (-5.15%)
    At close: Jun 13, 2025, 3:59 PM
    6.40
    2.24%
    After-hours: Jun 13, 2025, 05:39 PM EDT

    Emergent BioSolutions Statistics

    Share Statistics

    Emergent BioSolutions has 54.28M shares outstanding. The number of shares has increased by 3.69% in one year.

    Shares Outstanding

    n/a
    		 54.28M

    Shares Change (YoY)

    n/a
    		 3.69%

    Shares Change (QoQ)

    n/a
    		 0.28%

    Owned by Institutions (%)

    n/a
    		 65.41%

    Shares Floating

    n/a
    		 51.91M

    Failed to Deliver (FTD) Shares

    n/a
    		 12,531

    FTD / Avg. Volume

    n/a
    		 1.04%

    Short Selling Information

    The latest short interest is 7.83M, so 14.43% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 7.83M

    Short % of Shares Out

    n/a
    		 14.43%

    Short % of Float

    n/a
    		 14.58%

    Short Ratio (days to cover)

    n/a
    		 5.66

    Valuation Ratios

    The PE ratio is -2.66 and the forward PE ratio is 5.28. Emergent BioSolutions's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -2.66

    Forward PE

    n/a
    		 5.28

    PS Ratio

    n/a
    		 0.5

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 1.05

    P/FCF Ratio

    n/a
    		 14.15

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Emergent BioSolutions.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 3.69, with a Debt / Equity ratio of 1.37.

    Current Ratio

    n/a
    		 3.69

    Quick Ratio

    n/a
    		 1.77

    Debt / Equity

    n/a
    		 1.37

    Debt / EBITDA

    n/a
    		 17.99

    Debt / FCF

    n/a
    		 18.54

    Interest Coverage

    n/a
    		 -1.53

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,126,222.22

    Profits Per Employee

    n/a
    		 $-211,777.78

    Employee Count

    n/a
    		 900

    Asset Turnover

    n/a
    		 0.73

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 47.7M

    Effective Tax Rate

    n/a
    		 -33.38%

    Stock Price Statistics

    The stock price has increased by 1.46% in the last 52 weeks. The beta is 2.11, so Emergent BioSolutions's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.11

    52-Week Price Change

    n/a
    		 1.46%

    50-Day Moving Average

    n/a
    		 5.61

    200-Day Moving Average

    n/a
    		 7.77

    Relative Strength Index (RSI)

    n/a
    		 50.53

    Average Volume (20 Days)

    n/a
    		 1,200,138

    Income Statement

    In the last 12 months, Emergent BioSolutions had revenue of 1.01B and earned -190.6M in profits. Earnings per share was -3.6.

    Revenue

    n/a
    		 1.01B

    Gross Profit

    n/a
    		 305.2M

    Operating Income

    n/a
    		 -108.7M

    Net Income

    n/a
    		 -190.6M

    EBITDA

    n/a
    		 36.9M

    EBIT

    n/a
    		 -71.9M

    Earnings Per Share (EPS)

    n/a
    		 -3.6
    Full Income Statement

    Balance Sheet

    The company has 99.5M in cash and 663.7M in debt, giving a net cash position of -564.2M.

    Cash & Cash Equivalents

    n/a
    		 99.5M

    Total Debt

    n/a
    		 663.7M

    Net Cash

    n/a
    		 -564.2M

    Retained Earnings

    n/a
    		 -212.4M

    Total Assets

    n/a
    		 1.43B

    Working Capital

    n/a
    		 594.9M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 58.7M and capital expenditures -22.9M, giving a free cash flow of 35.8M.

    Operating Cash Flow

    n/a
    		 58.7M

    Capital Expenditures

    n/a
    		 -22.9M

    Free Cash Flow

    n/a
    		 35.8M

    FCF Per Share

    n/a
    		 0.68
    Full Cash Flow Statement

    Margins

    Gross margin is 30.11%, with operating and profit margins of -10.72% and -18.8%.

    Gross Margin

    n/a
    		 30.11%

    Operating Margin

    n/a
    		 -10.72%

    Pretax Margin

    n/a
    		 -14.1%

    Profit Margin

    n/a
    		 -18.8%

    EBITDA Margin

    n/a
    		 3.64%

    EBIT Margin

    n/a
    		 -10.72%

    FCF Margin

    n/a
    		 3.53%

    Dividends & Yields

    EBS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for EBS is $15, which is 139.6% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $15

    Price Target Difference

    n/a
    		 139.6%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 1.27

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist